<DOC>
	<DOCNO>NCT01911728</DOCNO>
	<brief_summary>A drug-drug interaction study investigate potential pharmacokinetic interaction MDV3100 cocktail substrates pioglitazone ( CYP2C8 substrate ) , S-warfarin ( CYP2C9 substrate ) , omeprazole ( CYP2C19 substrate ) , midazolam ( CYP3A4 substrate ) .</brief_summary>
	<brief_title>Drug-drug Interaction Study With MDV3100 Cocktail Substrates</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell feature ; Ongoing androgen deprivation therapy gonadotropin release hormone ( GnRH ) analogue orchiectomy ( i.e. , medical surgical castration ) ; Progressive disease prostate specific antigen ( PSA ) image whether chemotherapy set medical surgical castration . Disease progression study entry define one follow 3 criterion : PSA progression define minimum 3 rise PSA level interval ≥1 week determination . The PSA value pre investigational period ≥2 μg/L ( 2 ng/mL ) ; Soft tissue disease progression define Response Evaluation Criteria Solid Tumors , version 1.1 ( RECIST 1.1 ) soft tissue disease ( see Appendix A ) ; Bone disease progression define two new lesion bone scan . Confirmed CYP2C8 , CYP2C9 , CYP2C19 poor metabolizer status base genotyping analysis ; Absolute neutrophil count &lt; 1,500/μL , platelet count &lt; 100,000/μL , hemoglobin &lt; 5.6 mmol/L ( 9 g/dL ) screening period ( NOTE : patient may receive growth factor blood transfusion within 7 day prior hematologic laboratory value obtain screen period ) ; Total bilirubin &gt; 1.5 time , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2 time upper limit normal screening period ; Creatinine &gt; 177 μmol/L ( 2 mg/dL ) screening period ; Albumin &lt; 30 g/L ( 3.0 g/dL ) screening period ; Treatment androgen receptor antagonist ( bicalutamide , flutamide , nilutamide ) , 5 α reductase inhibitor ( finasteride , dutasteride ) , estrogens , chemotherapy within 4 week prior enrollment ( Day 1 visit ) plan initiate treatment treatment study ; Use herbal product may decrease PSA level ( e.g. , saw palmetto ) systemic corticosteroid great equivalent 10 mg prednisone/prednisolone per day within 4 week prior enrollment ( Day 1 visit ) plan initiate treatment treatment study ; Structurally unstable bone lesion suggest impending fracture ; History seizure , include febrile seizure , loss consciousness , transient ischemia attack within 12 month prior enrollment ( Day 1 visit ) , condition may predispose seizure ( e.g. , prior stroke , brain arteriovenous malformation , head trauma loss consciousness require hospitalization )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Enzalutamide</keyword>
	<keyword>MDV3100</keyword>
	<keyword>Drug-Drug Interaction</keyword>
	<keyword>Xtandi</keyword>
</DOC>